Published in final edited form as:

Antiviral Res. 2008 August ; 79(2): 133–135. doi:10.1016/j.antiviral.2008.01.155.

Effect of Oral Treatment with (S)-HPMPA, HDP-(S)-HPMPA or ODE-(S)-HPMPA on Replication of Murine Cytomegalovirus (MCMV) or Human Cytomegalovirus (HCMV) in Animal Models

Debra C. Quenelle¹, Deborah J. Collins¹, Latisha R. Pettway¹, Carol B. Hartline¹, James R. Beadle², W. Brad Wan², Karl Y. Hostetler², and Earl R. Kern¹

¹University of Alabama School of Medicine, Birmingham, AL

²Department of Medicine, University of California, San Diego, CA, USA

Summary

We utilized BALB/c mice infected with murine CMV (MCMV) or severe combined immunodeficient (SCID) mice implanted with human fetal tissue and infected with HCMV to determine the efficacy of (S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine ((S)-HPMPA), hexadecyloxypropyl-(S)-HPMPA (HDP-(S)-HPMPA), or octadecyloxyethyl-(S)-HPMPA (ODE-(S)-HPMPA). In MCMV-infected BALB/c mice, oral HDP-(S)-HPMPA at 30 mg/kg significantly reduced mortality when started 24 - 48 h post inoculation. In the experimental HCMV infection, oral administration of vehicle or 10 mg/kg of (S)-HPMPA, HDP-(S)-HPMPA or ODE-(S)-HPMPA was initiated 24 h after infection and continued for 28 consecutive days. Cidofovir (CDV), at 20 mg/kg given i.p., was used as a positive control. HDP-(S)-HPMPA or ODE-(S)-HPMPA significantly reduced viral replication compared to vehicle treated mice, while oral (S)-HPMPA was ineffective.

Keywords

cytomegalovirus; antiviral; animal models; phosphonate nucleotides

Synthesis of orally active alkoxyalkyl esters of cidofovir (CDV) and (S)-9-[3-hydroxy-2-(phosphonomethoxy)propyl]adenine ((S)-HPMPA) have resulted in modified compounds that are highly effective in vitro against both orthopoxviruses and cytomegalovirus (CMV) (Beadle et al., 2006, Keith et al., 2004). The EC₅₀ values of (S)-HPMPA, hexadecyloxypropyl-(S)-HPMPA (HDP-(S)-HPMPA), octadecyloxyethyl-(S)-HPMPA (ODE-(S)-HPMPA) and CDV against murine CMV (MCMV) and HCMV, respectively, were 0.16, 0.002, 0.003 and 0.04 for MCMV and 0.82, 0.003, 0.003 and 1.2 for HCMV (Beadle et al., 2006). (S)-HPMPA, HDP-(S)-HPMPA and ODE-(S)-HPMPA were synthesized as reported previously (Quenelle et al., 2007). These compounds were given orally to mice by gavage once daily using a 0.2 ml volume. CDV was given once daily i.p. as a positive control in a 0.1 ml volume.

Corresponding author: Debra C. Quenelle, D.V.M., Ph.D., The University of Alabama at Birmingham, School of Medicine, Department of Pediatrics, CHB 128, 1600 6th Avenue South, Birmingham, AL 35233, Ph. (205) 934-1990, Fax (205) 975-1992, E-mail: dquenell@uab.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

MCMV infections were initiated by i.p. inoculation of BALB/c mice with 6×10^4 PFU/mouse, approximately the 90% lethal dose (Kern et al., 2000a,b), and HDP-(S)-HPMPA at doses of 30, 10 or 3 mg/kg was administered beginning 24, 48 or 72 h post viral inoculation and the results are summarized in Table 1. When HDP-(S)-HPMPA was administered to BALB/c mice for 5 days using 30, 10 or 3 mg/kg once daily there was no observed toxicity as indicated by mortality or clinical signs (data not shown). When HDP-(S)-HPMPA was given at 30 mg/kg, mortality due to MCMV was reduced significantly ($p < 0.001$) even when initiation of treatment was delayed until 48 h post viral inoculation. There appears to be a reasonable dose response with HDP-(S)-HPMPA. However, CDV, the positive control, was more effective in preventing mortality.

HCMV infections were initiated by direct intra-xenograft inoculation of human fetal tissues implanted beneath the renal capsule of SCID mice (Bidanset et al., 2004; Kern et al., 2004a,b,c) using 4,700 PFU of HCMV (strain Toledo). Six to 12 implants were sampled on days 14, 21, 28, and 35, homogenized, and frozen at -70°C until assayed for HCMV using a plaque assay in human foreskin fibroblasts (Bidanset et al., 2004; Kern et al., 2004a,b,c). When HDP-(S)-HPMPA or ODE-(S)-HPMPA was given orally once daily for 28 days at 10 mg/kg to SCID mice inoculated with HCMV, a significantly reduced number of positive biopsy samples were found on day 28 and days 14-35, respectively, and HCMV titers in biopsy samples was reduced significantly ($p < 0.05$) by 1.4 to 2.8 logs (Table 2). The (S)-HPMPA-treated group had reduced numbers of positive implants on day 14 and CDV was active at all time points. Overall, the comparable order of efficacy of compounds in these studies was $\text{CDV} > \text{ODE-(S)-HPMPA} > \text{HDP-(S)-HPMPA} > \text{(S)-HPMPA}$.

Previous work with HDP-cidofovir (HDP-CDV) has shown that the addition of the ether lipid side chains improved oral bioavailability and also altered the cellular and systemic distribution in a way which markedly reduced the renal toxicity of CDV (Ciesla et al., 2003). Esterification of (S)-HPMPA with an alkoxyalkyl group alters drug metabolism, distribution and toxicity profile. The hexadecyloxypropyl esters of CDV and (S)-HPMPA show gastrointestinal toxicity at high oral doses but no evidence of kidney or liver toxicity (Hostetler, unpublished observations, 2007). The leading active compound identified in these studies was ODE-(S)-HPMPA, and additional work is clearly needed to further investigate the toxicity and the potential efficacy of these acyclic nucleoside phosphonate analogues against CMV and other herpesvirus infections.

Acknowledgements

This work was supported by Public Health Service Contract Number NO1-AI-15439, from NIAID, NIH, Bethesda, Md., and by NIH grants EY-07366, AI-066499, AI-064615, AI-074057 and by the Department of the Army, Grant No. 17-01-2-0071. The U.S. Army Medical Research Acquisition Activity, Ft. Detrick, Md., is the awarding acquisition office.

ERK and KYH have equity interests and serve as consultants to Chimerix, Inc. The terms of these arrangements have been reviewed and approved by the University of Alabama at Birmingham and the University of California, San Diego, respectively, in accordance with their conflict of interest policies.

References

- Beadle JR, Wan WB, Ciesla SL, Keith KA, Hartline C, Kern ER, Hostetler KY. Synthesis and antiviral evaluation of alkoxyalkyl derivatives of 9-(S)-(3-Hydroxy-2-phosphonmethoxypropyl)adenine against cytomegalovirus and orthopoxviruses. *J Med Chem* 2006;49:2010–2015. [PubMed: 16539388]
- Bidanset DJ, Beadle JR, Wan WB, Hostetler KY, Kern ER. Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection. *J Infect Dis* 2004;190:499–503. [PubMed: 15243923]

- Ciesla SL, Trahan J, Wan WB, Beadle JR, Aldern KA, Painter GR, Hostetler KY. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes accumulation in kidney. *Antiviral Res* 2003;59:163–171. [PubMed: 12927306]
- Keith KA, Wan WB, Ciesla SL, Beadle JR, Hostetler KY, Kern ER. Inhibitory activity of alkoxyalkyl and alkyl esters of cidofovir and cyclic cidofovir against orthopoxvirus replication in vitro. *Antimicrob Agents Chemother* 2004;48:1869–1871. [PubMed: 15105146]
- Kern ER, Bidanset DJ, Hartline CB, Yan Z, Zemlicka J, Quenelle DC. Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections. *Antimicrob Agents Chemother* 2004a;48:4745–4753. [PubMed: 15561852]
- Kern ER, Collins DJ, Wan WB, Beadle JR, Hostetler KY, Quenelle DC. Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir. *Antimicrob Agents Chemother* 2004b;48:3516–3522. [PubMed: 15328119]
- Kern ER, Hartline CB, Rybak RJ, Drach JC, Townsend LB, Biron KK, Bidanset DJ. Activities of benzimidazole D- and L- ribonucleosides in animal models of cytomegalovirus infections. *Antimicrob Agents Chemother* 2004c;48:1749–1755. [PubMed: 15105130]
- Quenelle DC, Collins DJ, Herrod BP, Keith KA, Trahan J, Beadle JR, Hostetler KY, Kern ER. Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice. *Antimicrob Agents Chemother* 2007;51:3940–3947. [PubMed: 17846137]

Effect of Oral Treatment with HDP-(S)-HPMPA on the Mortality of BALB/c Mice Inoculated Intraperitoneally with MCMV

Table 1

Treatment ^a	Mortality			P-value ^b	MDD±STDEV ^c	P-value ^d
	Number	Percent				
Vehicle- deionized water + 24 h	14/15	93			5.6±0.5	
CDV 10 mg/kg, i.p.	0/15	0		<0.001		
HDP-(S)-HPMPA 30 mg/kg	1/15	7		<0.001	6.0	NS ^e
HDP-(S)-HPMPA 10 mg/kg	2/15	13		<0.001	6.0±0	NS
HDP-(S)-HPMPA 3 mg/kg	15/15	100		NS	6.3±0.6	<0.01
Vehicle- deionized water +48 h	15/15	100			5.7±0.6	
CDV 10 mg/kg, i.p.	0/15	0		<0.001		
HDP-(S)-HPMPA 30 mg/kg	5/15	33		<0.001	9.0±3.1	<0.05
HDP-(S)-HPMPA 10 mg/kg	14/15	93		NS	6.4±0.5	<0.01
HDP-(S)-HPMPA 3 mg/kg	10/15	67		<0.05	6.6±1.1	<0.05
Vehicle- deionized water +72 h	15/15	0			5.2±0.6	
CDV 10 mg/kg, i.p.	5/15	33		<0.001	7.4±3.0	0.08
HDP-(S)-HPMPA 30 mg/kg	15/15	100		NS	6.0±0.8	<0.01
HDP-(S)-HPMPA 10 mg/kg	15/15	100		NS	5.7±0.8	0.04
HDP-(S)-HPMPA 3 mg/kg	15/15	100		NS	5.5±0.5	NS

^a CDV was prepared in sterile saline and delivered i.p. in 0.1 ml doses. HDP-(S)-HPMPA was prepared in deionized water and delivered p.o. in 0.2 ml doses. Animals were treated once daily for five days beginning 24, 48 or 72 h after viral inoculation.

^b Statistical significance determined for mortality rates by two-tailed Fisher's exact test with p<0.05 considered significant when compared to vehicle-treated controls.

^c MDD = Mean Day of Death.

^d Statistical significance determined for mean day of death by Mann-Whitney U rank sum with p<0.05 considered significant when compared to vehicle-treated controls.

^e NS=Not significant.

Table 2
Effect of Oral Treatment with (S)-HPMPA, HDP-(S)-HPMPA or ODE-(S)-HPMPA on Infection rates and Viral Titers in SCID-hu/Thymus Liver Implant Tissues Inoculated with HCMV

Treatment ^a	Parameter	Days Post Infection			
		14	21	28	35
Vehicle - water	% positive (#) ^b	83 (10/12)	75 (9/12)	45 (5/11)	36 (4/11)
	Log ₁₀ PFU/g ^c	5.6±5.9	4.9±5.1	4.8±5.1	4.7±4.9
CDV (i.p.) 20 mg/kg	% positive (#)	0 (0/6) ^d	0 (0/6) ^d	0 (0/2)	0 (0/2)
	Log ₁₀ PFU/g	0±0	0±0	0±0	0±0
(S)-HPMPA 10 mg/kg	% positive (#)	33 (4/12) ^d	42 (5/12)	50 (5/10)	50 (4/8)
	Log ₁₀ PFU/g	4.8±5.3	4.7±5.3	4.5±4.8	4.8±4.9
HDP-(S)-HPMPA 10 mg/kg	% positive (#)	42 (5/12)	70 (7/10)	9 (1/11) ^d	40 (4/10)
	Log ₁₀ PFU/g	4.8±5.1	3.5±3.8 ^d	3.4±3.9 ^d	4.3±4.6
ODE-(S)-HPMPA 10 mg/kg	% positive (#)	0 (0/12) ^d	33 (4/12) ^d	11 (1/9) ^d	13 (1/8) ^d
	Log ₁₀ PFU/g	0±0	4.2±4.6	2.1±2.6 ^d	4.4±4.9

^aTreatments were administered once daily for 28 consecutive days by oral gavage beginning 24 h post viral inoculation. CDV was administered i.p. as the positive control.

^bNumber of positives evaluated by 2-tailed Fisher's Exact test with $p < 0.05$ considered significant.

^cTiters are shown as Log₁₀ plaque forming units per gram of biopsy tissue and evaluated by stratified Wilcoxon rank sum test with $p < 0.05$ considered significant. The results obtained throughout the entire 28-day treatment period were used to calculate significance.

^dSignificant ($p < 0.05$).